首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.
【24h】

A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

机译:通过宿主非反应性抗第三方中央记忆CD8 T细胞消除残留淋巴瘤细胞的新方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Generation of T cells endowed with graft-versus-leukemia (GVL) and depleted of graft-versus-host (GVH) activity represents a highly desirable goal in bone marrow transplantation (BMT). Here, we demonstrate that donor anti-third-party CD8 T cells with central memory phenotype (Tcm) exhibit marked GVL reactivity through a unique T-cell receptor-independent mechanism. Thus, in a residual disease mouse model, Tcm therapy following autologous BMT led to significant survival prolongation, with 30% to 40% of the treated mice displaying long-term tumor-free survival. A more impressive finding was that infusion of donor Tcm in an allogeneic model rapidly eliminated residual lymphoma cells and led to long-term survival of 100% in the absence of GVH disease. Collectively, the strong GVL reactivity of anti-third-party Tcm, coupled with their demonstrated enhancement of bone marrow allografting, suggests that the use of Tcm therapy in conjunction with allogeneic T-cell-depleted BMT could be of particular benefit in patients with B-cell malignancies who cannot tolerate intensive myeloablative conditioning.
机译:赋予移植物抗白血病(GVL)并消除移植物抗宿主(GVH)活性的T细胞的产生代表了骨髓移植(BMT)的高度目标。在这里,我们证明具有中央记忆表型(Tcm)的供体抗第三方CD8 T细胞通过独特的T细胞受体独立机制表现出明显的GVL反应性。因此,在残留疾病的小鼠模型中,自体BMT后的Tcm治疗导致显着的生存期延长,其中30%至40%的治疗小鼠表现出长期无肿瘤生存期。一个更令人印象深刻的发现是在同种异体模型中输注供体Tcm可以快速消除残留的淋巴瘤细胞,并在不存在GVH疾病的情况下导致100%的长期存活。总的来说,抗第三方Tcm的强GVL反应性,加上其已证明的骨髓同种异体移植的增强,表明与同种异体T细胞耗尽的BMT结合使用Tcm治疗可能对B型患者特别有益。不能耐受强化清髓性调理的细胞恶性肿瘤。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号